Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer
A phase 1/2 trial of XNW5004, Enzalutamide in prostate cancer, run by Evopoint Biosciences Inc., now recruiting.
Overview
Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer is a phase 1/2 interventional study registered as NCT06702995 by Evopoint Biosciences Inc., with 307 participants planned, started 2023-04-19 and due to reach its primary completion in 2026-05-13. Interventions recorded: XNW5004, enzalutamide. Conditions listed: Metastatic Castrate-Resistant Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialClinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma
Shares XNW5004, Evopoint Biosciences.
- TrialA Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Shares XNW5004, Evopoint Biosciences.
- TrialStudy of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer
Shares Enzalutamide, Prostate cancer.
- TrialClinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma
Shares XNW5004, Evopoint Biosciences.
- TrialAn Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormo
Shares Enzalutamide, Prostate cancer.
- TrialZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
Shares Enzalutamide, Prostate cancer.
- TrialAn Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Canc
Shares Enzalutamide, Prostate cancer.
- TrialA Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Shares Enzalutamide, Prostate cancer.